Dobecure, s.l. we are a biomedical investigation company, aimed to develop different therapies based in the use of synthetic inhibitors of fibroblast growth factor (FGF), for diseases associated with inflammation and angiogenesis. In Dobecure we focus our research activity in ophthalmology diseases (age-related macular degeneration, both wet and dry, uveitis, corneal edema and herpetic queratitis). We are also exploring other research fields such as tendinitis and tendinosis, cold sores, otitis and allergic rhinitis, and some rare diseases. Headquartered in Madrid – Spain, Dobecure is a private entity, opened to any investment that shares its objectives and values, mainly referred to the medical investigation.
| Website | http://www.dobecure.com |
| Revenue | $3 million |
| Employees | 2 (0 on RocketReach) |
| Founded | 2016 |
| Technologies |
JavaScript
,
HTML
,
PHP
+12 more
(view full list)
|
| Industry | Biotechnology Research, Manufacturing General, Manufacturing |
| Keywords | Biomedical Research, Therapeutic Development, Drug Development, Inflammation Treatment, Disease Treatment, Pharmaceutical Research, Novel Therapies, Targeted Therapies, Biotechnology, Clinical Development |
| Competitors | Greenleaf Wellness, WELLNESS FUSION, LLC, Inspire Wellness Psychology, Align Health, wellNEST, Bene Fit Therapies, Mindful Wellness Brands, Peak Wellness (view competitors) |
| SIC | SIC Code 28 Companies, SIC Code 21 Companies, SIC Code 20 Companies, SIC Code 283 Companies |
| NAICS | NAICS Code 32 Companies, NAICS Code 312 Companies, NAICS Code 325 Companies, NAICS Code 31 Companies, NAICS Code 3122 Companies, NAICS Code 33 Companies |
Looking for a particular DobeCure employee's phone or email?
DobeCure Questions
The DobeCure annual revenue was $3 million in 2026.
The NAICS codes for DobeCure are [32, 312, 325, 31, 3122, 33].
The SIC codes for DobeCure are [28, 21, 20, 283].
Related Companies
